about
Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantationModern approaches to incompatible kidney transplantationTreatment options and strategies for antibody mediated rejection after renal transplantationPretransplant IgG reactivity to apoptotic cells correlates with late kidney allograft loss.B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation.Haemodialysing babies weighing <8 kg with the Newcastle infant dialysis and ultrafiltration system (Nidus): comparison with peritoneal and conventional haemodialysisDiagnosis and management of antibody-mediated rejection: current status and novel approaches.Impact of pretransplant rituximab induction on highly sensitized kidney recipients: comparison with non-rituximab group.Tolerogenic therapies in transplantation.High-dosage intravenous immunoglobulin-associated macrovacuoles are associated with chronic tubulointerstitial lesion worsening in renal transplant recipients.Increased C4d in post-reperfusion biopsies and increased donor specific antibodies at one-week post transplant are risk factors for acute rejection in mild to moderately sensitized kidney transplant recipients.Portal venous donor-specific transfusion in conjunction with sirolimus prolongs renal allograft survival in nonhuman primates.Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology.Advances in diagnosing and managing antibody-mediated rejection.Current approaches to the management of highly sensitized kidney transplant patients.Regulation of immunity and inflammation by intravenous immunoglobulin: relevance to solid organ transplantation.Detection of anti-HLA antibodies by solid-phase assay in kidney transplantation: friend or foe?Cardiac antibody-mediated rejection.B Cell Immunity in Solid Organ Transplantation.Renal transplantation in sensitized children and young adults: a nationwide approach.Outcomes in the highest panel reactive antibody recipients of deceased donor kidneys under the new kidney allocation system.Phenotype, distribution and alloreactive properties of memory T cells from cynomolgus monkeysLate kidney dysfunction in a kidney transplant recipientB-cell-dependent memory T cells impede nonmyeloablative mixed chimerism induction in presensitized mice.Acute cellular and antibody-mediated rejection of the pancreas allograft: incidence, risk factors and outcomes.Panel-reactive antibody levels and renal transplantation rates in sensitized patients after desensitization and human leucocyte antigen amino acid residue matching.Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab.Porcine to Human Heart Transplantation: Is Clinical Application Now Appropriate?Association between the polymorphism of HLA and ESRD in Dalian Han population located in north of China.The role of initial hemodialysis vascular access in the outcome of subsequent kidney transplantation.Living donor kidney transplantation in crossmatch-positive patients enabled by peritransplant immunoadsorption and anti-CD20 therapy.Effect of Treatment With Tabalumab, a B Cell-Activating Factor Inhibitor, on Highly Sensitized Patients With End-Stage Renal Disease Awaiting Transplantation.Autologous Mesenchymal Stromal Cells Prevent Transfusion-elicited Sensitization and Upregulate Transitional and Regulatory B Cells
P2860
Q26780271-AC7D4F25-E484-4CBA-8338-DCEC850A8771Q27010224-54B1FE36-3AB4-47CF-A3B2-5A999F939F06Q27021397-8147C6FF-A431-4CCA-9E70-56D921D22CBCQ33998148-3AE670A3-32E8-456A-80D4-6A9A809FDE6EQ34159016-B05DAE3A-FEB0-4084-B0D9-38CB8C3E619BQ34204510-2DDD0CAE-69AF-47E2-9587-6443D5628FBBQ34841849-985B5542-CD53-49DF-87EC-1995BD79C1C6Q36028067-F1A7637E-D4C4-4C1F-864B-5FFF827F4793Q36102133-7FB54499-F37C-4983-9971-38CA928E51A6Q36843406-76A0A680-6C7F-46CB-A116-79209345968EQ36901669-2B724D7D-21FE-4DD9-9DE6-D85D1132C26EQ37373575-4E842318-73CE-42FF-BD47-A5C08FF2120EQ37626123-2B846F0F-1D64-4F12-B724-9A33D876820EQ37676032-2956C060-9F7A-465B-88E8-438F08161685Q37836967-BC8C5296-AF4A-4C69-A104-296AF1614E64Q37877263-74274034-D01E-4C8E-AE48-4DE246605C41Q38001495-DC09E72C-876D-49D1-8D98-69449AB4974EQ38002449-9F3E9EE1-0E3E-40E9-BE67-8441F0E38193Q39101892-DA371C55-F4E3-4254-84A5-7E1C693A75B6Q39289605-091E1ADF-FE76-48F9-A311-5F83A37BF48BQ40405351-33C42AC8-6A1F-4993-901D-5DD1574FBA82Q41510934-209D1FC5-767D-42AE-98EF-C75963F2B507Q41834576-1F37E8D5-8545-4E6D-938F-76442D905E38Q42016816-8C1D57BD-D0B3-4E3A-A897-D1BF2ACE375BQ44075598-B3E6F866-2144-45EB-8A2B-BC0987E17540Q44205594-744913DD-5523-43EC-86A9-581AD1BC198BQ46921326-4B450B95-DCDA-40F3-B495-939F4C013C99Q47136558-F1FE6289-2C45-4BB4-A7CC-B41741D47A97Q48527007-406C9507-9CC1-4DDE-AE2C-AFD55ED0A6C2Q50111204-3F66785D-B8C0-455F-95B1-0FCC6A3C8EDFQ51413561-CDE2BA5F-7B20-43E8-898F-3B836229C60EQ52888455-48E78443-5E97-4DBD-8256-B9CE057163BDQ58700304-64020F43-5EC7-44B6-A729-CDAAF4EF7D42
P2860
description
2006 nî lūn-bûn
@nan
2006 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Presensitization: the problem and its management.
@ast
Presensitization: the problem and its management.
@en
Presensitization: the problem and its management.
@nl
type
label
Presensitization: the problem and its management.
@ast
Presensitization: the problem and its management.
@en
Presensitization: the problem and its management.
@nl
prefLabel
Presensitization: the problem and its management.
@ast
Presensitization: the problem and its management.
@en
Presensitization: the problem and its management.
@nl
P356
P1476
Presensitization: the problem and its management.
@en
P2093
Mark D Pescovitz
Stanley C Jordan
P304
P356
10.2215/CJN.01651105
P577
2006-04-12T00:00:00Z